Table 2: Theoretically predicted IC50 (μM) of curcumin, its in vivo metabolites, and degradation products for eight model enzymes.

From: How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies

Table 2: Theoretically predicted IC50 (μM) of curcumin, its in vivo metabolites, and degradation products for eight model enzymes.
InhibitorsAChEBACE-1HiV-1 PRHiV-2 PRALR1ALR2COX-2SERCA
Experimental IC50 using curcumin as inhibitor67.6946340471004825048>20049104935507~1551
Curcumin (keto)0.150.070.130.171.00.081.580.03
Curcumin (enol)0.090.360.220.285.10.091.660.01
Tetrahydrocurcumin1.861.200.911.690.811.320.150.05
Hexahydrocurcumin1.250.980.221.820.320.690.210.02
Octahydrocurcuminol0.681.790.060.120.300.640.410.01
Trans-6-(4′-hydroxy-3′-methoxy-phenyl)-2,4-dioxo-5-hexenal12.596.514.516.557.511.436.30.5
Feruloyl methane47.916512.624.587.15.4177.811.7
Ferulic acid60.7 (128.7)a,3219921.427511465 (61.4)a,3330.214.5
Ferulic aldehyde23.225211738.910512430.615.1
Vanillin60.447337215854915737.291.2
  1. aExperimental values using ferulic acid as inhibitor in parentheses.